

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

***FINANCIAL STATEMENTS AND
INDEPENDENT ACCOUNTANTS' REVIEW REPORT***

FOR THE YEARS ENDED JUNE 30, 2025 AND 2024



ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

**FINANCIAL STATEMENTS AND
INDEPENDENT ACCOUNTANTS' REVIEW REPORT
FOR THE YEARS ENDED JUNE 30, 2025 AND 2024
TABLE OF CONTENTS**

Independent Accountants' Review Report	1
--	---

Reviewed Financial Statements

Statements of Financial Position.....	3
Statement of Activities for the year ended June 30, 2025.....	4
Statement of Activities for the year ended June 30, 2024.....	5
Statement of Functional Expenses for the year ended June 30, 2025	6
Statement of Functional Expenses for the year ended June 30, 2024	7
Statements of Cash Flows.....	8
Notes to Financial Statements.....	9



INDEPENDENT ACCOUNTANTS' REVIEW REPORT

To the Board of Directors of
The Alzheimer's Disease Resource Center
200 Carleton Avenue
East Islip, NY 11730

We have reviewed the accompanying financial statements of the Alzheimer's Disease Resource Center, Inc. (hereinafter, the "Organization," a nonprofit corporation), which comprise the statements of financial position as of June 30, 2025 and 2024, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of the Organization's management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

Accountants' Responsibility

Our responsibility is to conduct the review engagements in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our reviews.



Accountants' Conclusion

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt About the Organization's Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Organization will continue as a going concern. As discussed in Note 9 to the financial statements, in September 2025, the Organization's Board of Directors approved a merger with Alzheimer's Disease and Related Disorders, New York City, Inc. (d/b/a CaringKind). Upon completion of the merger, the Organization is expected to dissolve during the year ending June 30, 2026, and therefore, substantial doubt exists about the Organization's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 9. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our conclusion is not modified with respect to this matter.

Cerin & Associates LLP

Bohemia, New York

October 20, 2025

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

STATEMENTS OF FINANCIAL POSITION

JUNE 30,

2025

2024

ASSETS

Current Assets:

Cash and cash equivalents.....	\$	361,312	\$	230,584
Restricted cash.....		32,488		32,488
Accounts receivable.....		-		2,000
Grants receivable.....		95,581		56,241
Investments, at fair value.....		2,018,882		1,902,015
Prepaid expenses.....		8,401		8,401

TOTAL CURRENT ASSETS		2,516,664		2,231,729
-----------------------------	--	-----------	--	-----------

Property and equipment, net of accumulated depreciation.....		28,386		31,486
Intangible assets, net of accumulated amortization.....		2,292		2,292
Security deposits.....		13,233		13,233
Operating lease right-of-use asset.....		158,452		240,944

TOTAL ASSETS	\$	2,719,027	\$	2,519,684
---------------------	----	-----------	----	-----------

LIABILITIES AND NET ASSETS

Current Liabilities:

Accounts payable and accrued expenses.....	\$	19,842	\$	18,597
Current portion of operating lease liability.....		96,631		90,968

TOTAL CURRENT LIABILITIES		116,473		109,565
----------------------------------	--	---------	--	---------

Operating lease liability, net of current portion.....		84,821		181,452
--	--	--------	--	---------

TOTAL LIABILITIES		201,294		291,017
--------------------------	--	---------	--	---------

Net Assets:

Without donor restrictions.....		2,485,245		2,196,179
With donor restrictions.....		32,488		32,488

TOTAL NET ASSETS		2,517,733		2,228,667
-------------------------	--	-----------	--	-----------

TOTAL LIABILITIES AND NET ASSETS	\$	2,719,027	\$	2,519,684
---	----	-----------	----	-----------

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

**STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2025**

SUPPORT AND REVENUE	Without Donor Restrictions	With Donor Restrictions	Total
Contributions.....	\$ 247,526	\$ -	\$ 247,526
Government grants.....	370,000	-	370,000
Special events, net of \$11,456 direct benefits to donors.....	67,905	-	67,905
Program fees.....	16,016	-	16,016
Investment gain, net of investment fees.....	161,915	-	161,915
Other income.....	71,065	-	71,065
TOTAL SUPPORT AND REVENUE	934,427	-	934,427
EXPENSES			
Program services.....	442,772	-	442,772
Management and general.....	125,570	-	125,570
Fundraising.....	77,019	-	77,019
TOTAL EXPENSES	645,361	-	645,361
CHANGE IN NET ASSETS	289,066	-	289,066
Net assets, beginning of year.....	2,196,179	32,488	2,228,667
Net assets, end of year.....	<u>\$ 2,485,245</u>	<u>\$ 32,488</u>	<u>\$ 2,517,733</u>

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

**STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2024**

SUPPORT AND REVENUE	Without Donor Restrictions	With Donor Restrictions	Total
Contributions.....	\$ 218,406	\$ -	\$ 218,406
Government grants.....	169,610	-	169,610
Special events, net of \$12,913 direct benefits to donors.....	79,806	-	79,806
Program fees.....	7,136	-	7,136
Investment gain, net of investment fees.....	126,463	-	126,463
Other income.....	1,800	-	1,800
TOTAL SUPPORT AND REVENUE	603,221	-	603,221
EXPENSES			
Program services.....	432,083	-	432,083
Management and general.....	109,165	-	109,165
Fundraising.....	77,067	-	77,067
TOTAL EXPENSES	618,315	-	618,315
CHANGE IN NET ASSETS	(15,094)	-	(15,094)
Net assets, beginning of year.....	2,211,273	32,488	2,243,761
Net assets, end of year.....	<u>\$ 2,196,179</u>	<u>\$ 32,488</u>	<u>\$ 2,228,667</u>

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

**STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2025**

	Program Services	Management and General	Fundraising	Total
Salaries and wages.....	\$ 234,652	\$ 65,708	\$ 65,708	\$ 366,068
Payroll taxes and benefits.....	24,622	5,261	5,261	35,144
Advertising.....	9,535	2,853	3,989	16,377
Interest and bank fees.....	-	609	839	1,448
Office expense.....	-	702	-	702
Professional fees.....	27,750	20,257	907	48,914
Occupancy expense.....	89,485	-	-	89,485
Travel and entertainment.....	7,140	1,276	45	8,461
Telephone.....	-	6,937	-	6,937
Insurance.....	-	4,330	-	4,330
Equipment lease.....	-	2,147	-	2,147
Dues and subscriptions.....	314	7,920	-	8,234
Utilities.....	10,226	-	-	10,226
Program expenses.....	38,083	-	-	38,083
Repairs and maintenance.....	-	4,200	-	4,200
Payroll processing.....	965	270	270	1,505
Depreciation and amortization expense.....	-	3,100	-	3,100
TOTAL EXPENSES	\$ 442,772	\$ 125,570	\$ 77,019	\$ 645,361

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

**STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2024**

	Program Services	Management and General	Fundraising	Total
Salaries and wages.....	\$ 203,575	\$ 64,575	\$ 64,575	\$ 332,725
Payroll taxes and benefits.....	19,842	6,081	6,080	32,003
Advertising.....	29,390	-	5,267	34,657
Interest and bank fees.....	-	233	-	233
Office expense.....	160	2,316	-	2,476
Professional fees.....	15,163	18,103	-	33,266
Occupancy expense.....	93,592	-	-	93,592
Travel and entertainment.....	9,092	-	-	9,092
Telephone.....	6,743	843	843	8,429
Insurance.....	4,333	5,348	-	9,681
Equipment lease.....	-	2,699	-	2,699
Dues and subscriptions.....	380	7,055	-	7,435
Utilities.....	9,299	-	-	9,299
Program expenses.....	36,689	-	-	36,689
Repairs and maintenance.....	-	1,610	-	1,610
Payroll processing.....	983	302	302	1,587
Depreciation and amortization expense.....	2,842	-	-	2,842
TOTAL EXPENSES	\$ 432,083	\$ 109,165	\$ 77,067	\$ 618,315

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED JUNE 30,

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets.....	\$ 289,066	\$ (15,094)
<u>Adjustment to reconcile change in net assets to net cash provided by/(used in) operating activities:</u>		
Depreciation and amortization expense.....	3,100	2,842
Net realized and unrealized gain on investments.....	(129,065)	(89,928)
Amortization of operating lease right-of-use asset.....	82,492	79,977
<u>Changes in operating assets and liabilities:</u>		
Accounts receivable.....	2,000	25,628
Grants receivable.....	(39,340)	9
Operating lease liability.....	(90,968)	(76,458)
Accounts payable and accrued expenses.....	1,245	1,112
NET CASH PROVIDED BY/(USED IN) OPERATING ACTIVITIES	118,530	(71,912)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of investments.....	(87,802)	(346,443)
Sales of investments.....	100,000	83,963
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES	12,198	(262,480)
NET CHANGE IN CASH AND CASH EQUIVALENTS	130,728	(334,392)
Cash and cash equivalents, beginning of year.....	263,072	597,464
Cash and cash equivalents, end of year.....	<u>\$ 393,800</u>	<u>\$ 263,072</u>
COMPONENTS OF CASH AND CASH EQUIVALENTS ON THE STATEMENTS OF FINANCIAL POSITION:		
Unrestricted cash and cash equivalents.....	\$ 361,312	\$ 230,584
Restricted cash and cash equivalents.....	32,488	32,488
TOTAL CASH AND CASH EQUIVALENTS	<u><u>\$ 393,800</u></u>	<u><u>\$ 263,072</u></u>

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of the Alzheimer's Disease Resource Center, Inc. (the "Organization") is presented to assist in understanding the Organization's financial statements. The financial statements and notes are representations of the Organization's management, which is responsible for the integrity and objectivity of the financial statements. These accounting policies conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and have been consistently applied in the preparation of the financial statements.

Organization: The Organization is located in East Islip, New York and was incorporated in the state of New York in September 1983. The Organization's mission is to provide care, support, and educational programs for families in need, and to be advocates for local families who are coping with Alzheimer's disease and other dementias.

Basis of Accounting: The accompanying financial statements have been prepared on the accrual basis of accounting. Revenue is recorded when earned and expenses are recorded when incurred.

Income Tax Status: The Organization is exempt from federal income tax under section 501(c)(3) of the Internal Revenue Code and is publicly supported as described in section 509(a). Donors may deduct contributions made to the Organization within the requirements of the Internal Revenue Code. The Organization has evaluated its activities for uncertain tax positions and has determined that there were no uncertain tax positions for the years ended June 30, 2025 and 2024. The Organization files an IRS Form 990 and respective state tax returns. These returns are subject to review and examination by federal and state taxing authorities. The Organization has determined that it has registered in all states where it is required to be registered.

Basis of Presentation: The Organization is required to report information regarding its financial position and activities according to two classes of net assets, as follows:

Net assets without donor restrictions - Net assets that are not subject to donor-imposed stipulations and may be expended for any purpose in performing the primary objectives of the Organization. These net assets may be used at the discretion of the Organization's management and the Board of Directors.

Net assets with donor restrictions - Net assets subject to donor-imposed stipulations or other stipulations that may or will be met, either by action of the Organization and/or the passage of time. Other donor restrictions may be perpetual in nature, whereby the donor may stipulate the funds be maintained in perpetuity. When a restriction expires, net assets with donor restrictions are reclassified annually to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

As of June 30, 2025 and 2024, the Organization had no net assets to be held in perpetuity.

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Cash and Cash Equivalents: The Organization considers all highly liquid investments with a maturity of three months or less to be cash equivalents.

Accounts Receivable: Receivables are stated at the amount management expects to collect from outstanding balances. The Organization considers receivables past due or delinquent when payments have not been received in a timely manner, and receivables are written off when management deems the possibility of collecting amounts due as completely unlikely. The Organization closely monitors outstanding balances for all receivables and adheres to a standard set of protocols for collection activities to be undertaken at certain times based upon delinquency status. Management estimates that all receivables at June 30, 2024 will be collected.

Investments: Investments in marketable securities with readily determinable fair values and all investments in debt securities are valued at their fair values in the statements of financial position. Unrealized gains and losses are included in investment income in the statements of activities.

Fair Value Measurement: Investments are stated at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring the most observable inputs to be used when available. The fair value hierarchy is categorized into three levels (see Note 2).

Property and Equipment: Property and equipment are stated at cost, if purchased, or fair value, if contributed. Maintenance and repairs are charged to expense and betterments of \$1,000 or more are capitalized. Depreciation and amortization expense are computed using the straight-line method over each asset's estimated useful life as follows:

Leasehold improvements	10 - 40 years
Computer hardware and software	3 - 5 years

Functional Expenses: Expenses have been summarized on a functional basis in the statements of activities and functional expenses. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Directly identifiable expenses are charged to program and supporting services. Management and general expenses include those expenses that are not directly identifiable with any other specific function but provide for the overall support and direction of the Organization. Those costs that cannot be directly assigned to one function are allocated to program and supporting services based upon reasonable allocation methodologies. Salaries and wages and related costs that are not directly assigned to one functional expense category are allocated based on management's estimate of personnel time spent.

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Contributions: The Organization recognizes contributions when donors make promises to give to the Organization that are, in substance, unconditional. Contributions that are restricted by donors are reported as increases in net assets without donor restrictions if the restrictions expire in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions.

When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions. Conditional contributions are accounted for as liabilities or are not recognized as revenue initially, until the barriers to entitlement are overcome, at which point contributions are recognized as unconditional and classified as either net assets with donor restrictions or net assets without donor restrictions.

Government Grants: Support from government grants is restricted as to the use specified in the grant agreement. Support from government grants is generally expended within a one-year cycle. The Organization recognizes government grants as revenue when eligible costs are incurred or services are provided. A receivable is recognized to the extent revenue earned exceeds cash advances. Conversely, deferred revenue and refundable advances are recorded when cash advances exceed support and revenue earned.

Special Events: Revenue from special events is recorded when performance obligations are satisfied, which is generally at the time the events take place. Costs incurred for which a donor receives a direct benefit are considered exchange transactions and are offset against the revenue earned. Other costs related to the event for which the donor does not receive a direct benefit are classified as fundraising costs in the accompanying statements of functional expenses.

Program Fees: Program fees are recorded as revenues at points in time when services are provided.

Advertising: Advertising costs are expensed as incurred. Such costs amounted to \$16,377 and \$34,657 for the years ended June 30, 2025 and 2024, respectively.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements: Effective for the year ended June 30, 2024, the Organization adopted Accounting Standards Codification ("ASC") 326, *Measurement of Credit Losses on Financial Instruments*, for all assets held at amortized cost basis, including receivables. Under this accounting standard, the pronouncement requires organizations to record an estimate of all expected future credit losses. The allowance for credit losses will be a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. The adoption of ASC 326 had no significant impact to the financial statements.

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Events Occurring After the Report Date: The Organization has evaluated events and transactions that occurred between July 1, 2025 and October 20, 2025, which is the date that the financial statements were available to be issued, for possible disclosure and recognition in the financial statements.

NOTE 2 - INVESTMENTS

The Organization presents investments in the statements of financial position at fair value. A fair value hierarchy has been established based on the observability of inputs to the evaluation of an asset or liability as of the measurement date. The three-level valuation techniques are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair value levels (Level 1, 2, and 3):

- Level 1: Level 1 instruments are valued using observable inputs that reflect quoted prices for identical assets or liabilities in active markets that the Organization has the ability to access at the measurement date. Level 1 assets include highly-liquid U.S. Treasury securities and exchange-traded equity securities.
- Level 2: Level 2 instruments are valued using observable inputs, other than quoted prices included in Level 1, for the asset or liability or prices for similar assets and liabilities. Most debt securities and some preferred stocks are model-priced by vendors using observable inputs and are classified within Level 2. Also included in the Level 2 category are derivative instruments that are priced using models with observable market inputs, including interest rates, foreign currency, and certain credit swap contracts.
- Level 3: Level 3 instruments are valued using valuations that are derived from techniques in which one or more of the significant inputs are unobservable (including assumptions about risk). Level 3 securities include less liquid securities such as highly structured and/or lower quality, asset-backed securities ("ABS") and commercial mortgage-backed securities ("CMBS"), including ABS backed by sub-prime loans, and private placement debt and equity securities. Because Level 3 fair values, by their nature, contain unobservable market inputs as there is no observable market for these assets and liabilities, considerable judgment is used to determine the Level 3 fair values. Level 3 fair values represent the Organization's best estimate of an amount that could be realized in a current market exchange absent actual market exchanges.

All of the investments held by the Organization are considered Level 1 investments because they are regularly traded and have quoted prices in active markets.

The fair and historic values of the Organization's investments by major security type are as follows at June 30, 2025:

	Fair Value	Historical Cost
Fixed income.....	\$ 592,204	\$ 574,608
Equities.....	1,225,070	1,093,439
Mutual funds.....	201,608	195,476
Total	<u>\$ 2,018,882</u>	<u>\$ 1,863,523</u>

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

NOTE 2 - INVESTMENTS (continued)

The fair and historic values of the Organization's investments by major security type are as follows at June 30, 2024:

	Fair Value	Historical Cost
Fixed income.....	\$ 490,880	\$ 370,538
Equities.....	1,123,830	1,105,514
Mutual funds.....	287,305	287,225
Total	<u>\$ 1,902,015</u>	<u>\$ 1,763,277</u>

The Organization invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect account balances, and the amounts reported in the accompanying statements of financial position.

NOTE 3 - PROPERTY AND EQUIPMENT

Property and equipment balances consisted of the following at June 30,:

	2025	2024
Leasehold improvements.....	\$ 23,597	\$ 23,597
Computer hardware and software.....	50,466	50,466
Property and equipment at cost.....	74,063	74,063
Less: accumulated depreciation and amortization	(45,677)	(42,577)
Net property and equipment	<u>\$ 28,386</u>	<u>\$ 31,486</u>

NOTE 4 - GOVERNMENT GRANTS AND RECEIVABLES

Grants receivable consists of a conditional promise to give that is expected to be collected in the future. The Organization was awarded \$365,000 during the years ended June 30, 2025 and 2024, which was administered by the New York State Department of Health ("DOH"). These grants are cost reimbursement grants, whereby payments are disbursed to the Organization only after documentation of services rendered are submitted and approved by DOH. The Organization performed services and submitted documentation for costs incurred of \$365,000 and \$168,750 during the years ended June 30, 2025 and 2024, respectively. Grant receivables were collected subsequent to year-end. Subsequent to year-end, the Organization was awarded a new contract for \$365,000 for the period April 1, 2025 through March 31, 2026, however, the contract has not been executed as of the report date.

NOTE 5 - NET ASSETS WITH DONOR RESTRICTIONS

The Organization's net assets with donor restrictions as of June 30, 2025 and 2024 were available to support the following:

Research.....	\$ 31,051
Gallery awards.....	1,437
Total.....	<u>\$ 32,488</u>

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

NOTE 6 - COMMITMENTS AND CONTINGENCIES

The Organization entered into a non-cancelable operating lease for its facility in East Islip, New York. The five year lease term commenced on May 1, 2022. Monthly payments in fiscal year 2025 were \$8,103 from May 2024 through April 2025 and increased to \$8,346 as of May 2025. Operating lease costs incurred during the years ended June 30, 2025 and 2024, inclusive of right-of-use asset amortization, totaled \$82,492 and \$79,977, respectively, and are included as part of occupancy expense in the statements of functional expenses. Operating cash flows from this operating lease totaled \$90,968 and \$76,458 for the years ended June 30, 2025 and 2024, respectively.

The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liability for the years ending June 30,:

2026.....	\$	100,649
2027.....		<u>85,961</u>
Total future minimum payments.....	\$	<u><u>186,610</u></u>

This lease had a remaining lease term of 22 months as of June 30, 2025 and was discounted at a rate of 2.92%.

NOTE 7 - CONCENTRATION OF RISK

Financial instruments that potentially subject the Organization to significant concentrations of credit risk consist principally of cash and cash equivalents and investments. The Organization maintains cash and investments in bank accounts with what it believes to be quality financial institutions which are insured by the Federal Deposit Insurance Corporation ("FDIC") and the Securities Investor Protection Corporation ("SIPC"). The Organization has not incurred any losses in such accounts to date. At times, balances held at financial institutions may be in excess of federally insured limits.

During the years ended June 30, 2025 and 2024, the Organization received approximately 59% and 44% of its support and revenue from three and two funders, respectively. As of June 30, 2025 and 2024, 100% of total grants receivable was due from one funder.

ALZHEIMER'S DISEASE RESOURCE CENTER, INC.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024

NOTE 8 - AVAILABILITY AND LIQUIDITY

The following represents the Organization's financial assets at June 30,:

	2025	2024
Cash and cash equivalents	\$ 361,312	\$ 230,584
Restricted cash.....	32,488	32,488
Accounts receivable.....	-	2,000
Grants receivable	95,581	56,241
Investments, at fair value	2,018,882	1,902,015
Total financial assets.....	2,508,263	2,223,328
Less amounts not available to be used for general operations:		
Net assets with donor restrictions.....	(32,488)	(32,488)
Financial assets available to meet general expenditures over the next twelve months.....	\$ 2,475,775	\$ 2,190,840

The Organization's goal is generally to maintain financial assets to meet ninety days of operating expenses (approximately \$158,000).

NOTE 9 - SUBSEQUENT EVENT

On September 7, 2025, the Organization's Board of Directors approved the merger with Alzheimer's Disease and Related Disorders, New York City, Inc. (d/b/a CaringKind) ("CaringKind"), a non-profit entity with a mission aligned to that of the Organization. As part of the merger, the Organization's by-laws will be amended to designate CaringKind as the sole member of the Organization. CaringKind will assume all assets and liabilities of the Organization and continue to operate its programs. The Organization will dissolve upon completion of the merger. The merger is subject to final approval by the New York State Attorney General.